NEW YORK, Dec. 30, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Innocoll Holdings plc ("Innocoll" or the "Company") (NASDAQ: INNL). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Innocoll and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On December 29, 2016, Innocoll announced that it had received a Refusal to File letter from the U.S. Food & Drug Administration ("FDA") with respect to the Company's New Drug Application for its lead product candidate XARACOLL, a postsurgical pain treatment. Innocoll stated that the FDA's letter informed the Company that XARACOLL should have been characterized as a drug/device combination, requiring Innocoll to submit further information.
On this news, Innocoll stock has fallen as much as $1.18, or 66.7%, during intraday trading on December 30, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-innocoll-holdings-plc---innl-300384267.html
SOURCE Pomerantz LLP